888-969-2592
Kalkine 0
countryflagCA

Exelixis Inc

Healthcare US EXEL

44.23USD
-0.64(1.43%)

Last update at 2025-07-18T16:53:00Z

Day Range

44.3345.13
LowHigh

52 Week Range

18.6424.34
LowHigh

Fundamentals

  • Previous Close 44.87
  • Market Cap5924.90M
  • Volume507796
  • P/E Ratio31.29
  • Dividend Yield-%
  • EBITDA229.59M
  • Revenue TTM1846.65M
  • Revenue Per Share TTM5.91
  • Gross Profit TTM 1553.15M
  • Diluted EPS TTM0.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 234.35M 294.15M 130.84M 398.11M 452.09M
Minority interest - - - - -
Net income 182.28M 231.06M 111.78M 321.01M 690.07M
Selling general administrative 459.86M 401.71M 293.36M 228.24M 206.37M
Selling and marketing expenses - - - - -
Gross profit 1553.15M 1382.10M 951.27M 934.68M 827.48M
Reconciled depreciation 20.88M 13.63M 9.14M 8.35M 7.77M
Ebit 180.61M 273.04M 100.92M 361.12M 444.32M
Ebitda 201.48M 286.67M 110.06M 369.47M 452.09M
Depreciation and amortization 20.88M 13.63M 9.14M 8.35M 7.77M
Non operating income net other -0.19700M -0.18400M 0.91M 0.68M 0.40M
Operating income 201.48M 286.67M 110.06M 369.47M 438.86M
Other operating expenses 1409.58M 1148.30M 877.48M 598.30M 414.97M
Interest expense 53.74M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision 52.07M 63.09M 19.06M 77.10M -237.97800M
Interest income 33.06M 7.67M 19.86M 27.96M 12.84M
Net interest income 33.06M 7.67M 19.86M 27.96M 12.84M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 52.07M 63.09M 19.06M 77.10M -237.97800M
Total revenue 1611.06M 1434.97M 987.54M 967.77M 853.83M
Total operating expenses 1351.67M 1095.43M 841.21M 565.21M 388.62M
Cost of revenue 57.91M 52.87M 36.27M 33.10M 26.35M
Total other income expense net 32.87M 7.49M 20.78M 28.64M 13.24M
Discontinued operations - - - - -
Net income from continuing ops 182.28M 231.06M 111.78M 321.01M 690.07M
Net income applicable to common shares 182.28M 231.06M 111.78M 321.01M 690.07M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2942.36M 3071.49M 2616.24M 2137.33M 1885.67M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 67.93M 62.21M 57.53M 57.01M 26.99M
Total liab 678.45M 583.06M 405.62M 258.22M 199.70M
Total stockholder equity 2263.91M 2488.43M 2210.61M 1879.11M 1685.97M
Deferred long term liab - - - - -
Other current liab 329.39M 285.11M 313.33M 181.03M 21.72M
Common stock 0.30M 0.32M 0.32M 0.31M 0.30M
Capital stock 0.30M 0.32M 0.32M 0.31M 0.30M
Retained earnings -173.35100M -34.22500M -216.50700M -447.57000M -559.35100M
Other liab - 68.53M 16.76M 4.48M 8.94M
Good will 63.68M 63.68M 63.68M 63.68M 63.68M
Other assets - 286.88M 197.54M 187.11M 185.32M
Cash 262.99M 501.19M 647.17M 319.22M 266.50M
Cash and equivalents - - - - -
Total current liabilities 394.28M 324.36M 337.59M 204.66M 142.75M
Current deferred revenue 5.41M 6.58M 8.74M - 106.72M
Net debt -73.05000M -311.02500M -595.89700M -270.13100M -215.76200M
Short term debt 25.71M - -8.73900M - 2.73M
Short long term debt - - - - -
Short long term debt total 189.94M 190.17M 51.27M 49.09M 50.74M
Other stockholder equity 2440.71M 2536.85M 2427.56M 2321.89M 2241.95M
Property plant equipment - 110.62M 149.15M 67.38M 48.89M
Total current assets 1317.96M 1618.76M 1834.75M 1445.39M 1011.19M
Long term investments 728.72M 756.73M 371.11M 332.31M 536.38M
Net tangible assets - 2424.74M 2048.76M 1815.43M 1622.29M
Short term investments 732.31M 807.27M 819.90M 887.32M 585.74M
Net receivables 237.41M 214.78M 282.65M 160.88M 119.07M
Long term debt - - - - -
Inventory 17.32M 33.30M 27.49M 20.97M 12.89M
Accounts payable 33.77M 32.67M 24.26M 23.63M 11.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.75000M -14.52100M -0.75800M 4.48M 3.07M
Additional paid in capital - - - - -
Common stock total equity - 0.32M - 0.31M 0.30M
Preferred stock total equity - - - - -
Retained earnings total equity - -34.22500M - -447.57000M -559.35100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 290.58M 131.00M 71.85M 11.31M
Deferred long term asset charges - - - - -
Non current assets total 1624.40M 1452.73M 781.49M 691.94M 874.48M
Capital lease obligations 189.94M 190.17M 51.27M 49.09M 50.74M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -334.47400M -385.95800M 21.34M -100.87000M -574.41300M
Change to liabilities - -37.22300M 66.10M 51.11M 44.12M
Total cashflows from investing activities - -524.41400M -42.88400M -131.21500M -587.24700M
Net borrowings - - - - -
Total cash from financing activities -546.05200M 0.59M -14.80100M -25.13200M 12.55M
Change to operating activities - -91.32400M 30.42M -25.83100M -5.72300M
Net income 207.76M 182.28M 231.06M 111.78M 321.01M
Change in cash -239.68300M -161.21400M 343.12M 52.63M -47.73800M
Begin period cash flow 502.68M 663.89M 320.77M 268.14M 315.88M
End period cash flow 262.99M 502.68M 663.89M 320.77M 268.14M
Total cash from operating activities 333.32M 362.61M 400.80M 208.98M 526.96M
Issuance of capital stock - - - - -
Depreciation 25.72M 20.88M 13.63M 9.14M 8.35M
Other cashflows from investing activities - -110.75000M -10.00000M -10.00000M -574.41300M
Dividends paid - - - - -
Change to inventory -12.97700M -11.68300M -13.20900M -21.89700M -5.73100M
Change to account receivables -22.62300M 66.85M -122.32400M -42.47000M 43.72M
Sale purchase of stock -579.50000M 23.89M -39.10800M -50.01800M 22.50M
Other cashflows from financing activities 33.45M -47.18600M 24.31M 24.89M -32.44500M
Change to netincome - 153.94M 195.12M 123.37M 127.69M
Capital expenditures 162.97M 138.46M 64.22M 30.34M 12.83M
Change receivables - 66.85M - -42.47000M 43.72M
Cash flows other operating - -12.42700M - -22.05200M -12.20500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -161.21400M - 52.63M -47.73800M
Change in working capital -13.97300M -12.79900M -39.01300M -40.14000M 67.08M
Stock based compensation 106.34M 107.57M 119.82M 105.07M 56.60M
Other non cash items 140.68M 125.04M 28.77M 7.87M 2.91M
Free cash flow 170.35M 224.16M 336.58M 178.64M 514.12M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EXEL
Exelixis Inc		 -0.64 1.43% 44.23 31.29 17.67 3.78 3.06 3.34 31.08
NVO
Novo Nordisk A/S		 -1.07 1.64% 64.22 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 65.44 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.81 0.39% 461.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -6.63 1.21% 543.37 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis Inc

1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

Key Executives

Name Title Year Born
Dr. Stelios Papadopoulos Ph.D. Co-Founder & Independent Chair of the Board 1948
Dr. Michael M. Morrissey Ph.D. CEO, Pres & Director 1961
Mr. Christopher J. Senner Exec. VP & CFO 1968
Dr. Peter Lamb Ph.D. Exec. VP of Scientific Strategy & Chief Scientific Officer 1961
Mr. Jeffrey J. Hessekiel J.D. Exec. VP, Gen. Counsel & Sec. 1969
Mr. Patrick J. Haley M.B.A., MBA Exec. VP of Commercial 1976
Dr. Dana T. Aftab Ph.D. Exec. VP of Bus. Operations NA
Ms. Susan T. Hubbard Exec. VP of Public Affairs & Investor Relations NA
Mr. Gregg Bernier VP of Marketing NA
Ms. Laura Dillard Exec. VP of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.